Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
57 studies found for:    human epidermal growth factor receptor type 2 (HER2)
Show Display Options
Rank Status Study
1 Not yet recruiting A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer
Condition: Breast Neoplasms
Intervention: Other: Local Therapy
2 Active, not recruiting Evaluation of Trastuzumab Without Chemotherapy as a Postoperative Adjuvant Therapy in HER2 Positive Elderly Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: trastuzumab;   Drug: chemotherapy
3 Recruiting A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Patients With Metastatic Her 2- Negative and Aggressive Disease Criteria
Condition: Metastatic Breast Cancer
Interventions: Drug: Bevacizumab;   Drug: Paclitaxel
4 Completed A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors
Condition: Tumors
Intervention: Drug: CUDC-101
5 Completed
Has Results
A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors
Conditions: Head and Neck Cancer;   Liver Cancer;   Breast Cancer;   Gastric Cancer;   Non-Small Cell Lung Cancer
Intervention: Drug: CUDC-101
6 Completed Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Condition: Head and Neck Cancer
Interventions: Drug: CUDC-101;   Drug: Cisplatin;   Radiation: Radiation Therapy
7 Completed Usefulness of Myocardial Deformation Imaging for Trastuzumab-induced Cardiotoxicity
Conditions: Left Ventricular Function Systolic Dysfunction;   Cardiotoxicity
Intervention:
8 Completed The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors
Condition: Solid Tumors
Intervention: Drug: Lapatinib and Sorafenib
9 Completed Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients
Condition: Neoplasms, Breast
Intervention: Drug: Lapatinib plus capecitabine
10 Recruiting Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
Conditions: Malignant Solid Tumour;   Breast Cancer;   Malignant Tumor of Colon;   GIST;   Ovarian Cancer
Interventions: Biological: HER-2 vaccine;   Biological: Extension HER-2 vaccine trial at OBD
11 Recruiting PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: PD0332991;   Drug: Anastrozole;   Drug: Goserelin;   Procedure: Surgery (standard of care);   Procedure: Tumor biopsy
12 Completed A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)
Condition: Cancer
Interventions: Biological: V930;   Biological: V932
13 Active, not recruiting Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
Condition: HER-2 Positive Breast Cancer
Intervention: Drug: Pertuzumab, Trastuzumab and Eribulin
14 Completed
Has Results
Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
Condition: Gastric Cancer, Gastroesophageal Junction Cancer
Intervention: Biological: Trastuzumab
15 Recruiting T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma
Condition: Glioblastoma
Intervention: Genetic: HER2-specific T cells
16 Recruiting Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
Condition: Sarcoma
Interventions: Genetic: Autologous HER2-specific T cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
17 Unknown  Her 2 Testing in Indian Patients With Gastric Cancer
Condition: Gastric Cancer
Intervention:
18 Recruiting Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer
Condition: HER2-positive Refractory Advanced Cancer
Intervention: Drug: Lapatinib
19 Recruiting Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies
Condition: Oncology
Intervention: Drug: Sym013
20 Active, not recruiting CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
Condition: Glioblastoma Multiforme (GBM)
Intervention: Genetic: Genetically modified HER.CAR CMV-specific CTLs

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.